COVID-19

covid-19

← back to Infectious Diseases

Summary

IDSA living guideline on pharmacologic treatment and prevention of COVID-19, updated through October 2025. Covers antiviral selection for mild-to-moderate disease (nirmatrelvir/ritonavir preferred, then remdesivir, then molnupiravir), immunomodulator selection for severe/critical hospitalized disease (corticosteroids plus baricitinib or tocilizumab; abatacept or infliximab as alternatives), and pre-exposure prophylaxis with pemivibart in immunocompromised hosts. Recommendations against hydroxychloroquine, lopinavir/ritonavir, ivermectin, colchicine, famotidine, and routine convalescent plasma in immunocompetent hospitalized patients.

Current guideline: IDSA COVID-19 Treatment Guidelines · download Anki sub-deck

Versions

• IDSA — IDSA COVID-19 Treatment Guidelines
  • Read the guideline: html · Anki deck
• NIH — NIH COVID-19 Treatment Guidelines
  • Read the guideline: html

---

Table of contents

• IDSA